Singular Genomics Systems, Inc.
OMICHealthcare · Laboratory Analytical Instruments · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|
| Revenue | $2.9M | $800,000 | $0 | — |
| Operating income | −$102.8M | −$93.5M | −$61.3M | −$27.5M |
| Net income | −$94.8M | −$90.9M | −$98.8M | −$27.9M |
| Total assets | $265.5M | $328.0M | $355.6M | $30.5M |
| Total liabilities | $86.5M | $67.7M | $19.5M | $12.9M |
| Equity | $179.0M | $260.3M | $336.2M | −$51.6M |
| EPS (diluted) | $-1.30 | $-1.28 | $-2.10 | — |
| Shares out. | 71.9M | 70.4M | 72.4M | 10.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2023- Operating margin
- −3531.5%
- Net margin
- −3257.3%
- Return on equity
- −53.0%
- Return on assets
- −35.7%
- Return on capital (ROCE)
- −41.6%
- Liabilities / assets
- 32.6%
- Debt / equity
- 0.48×
- Book value / share
- $2.49
- Revenue growth (YoY)
- 263.9%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2023- Altman Z″ (distress)
- -0.28distress
- Accruals / assets
- −8.0%clean
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 3 warning● 3 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Arch Venture Fund Ix, L.P.Passive (13G)May 15, 2025
- Flynn James EActivist (13D)Feb 25, 2025
- Domain Partners Ix, L.P.Passive (13G)Jan 16, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Completed an acquisition or disposition · New financial obligation · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Other material eventFeb 27, 2025
- Shareholder voteFeb 19, 2025
- Other material eventFeb 13, 2025
- Entered a material agreement · Other material eventDec 23, 2024
- Results of operationsNov 12, 2024
- Other material eventNov 4, 2024
- Other material eventSep 19, 2024
- Other material eventSep 12, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.